These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29333885)

  • 1. When biomarkers define a drug indication.
    Jørgensen JT
    Expert Rev Mol Diagn; 2018 Apr; 18(4):315-317. PubMed ID: 29333885
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
    Marcus L; Lemery SJ; Keegan P; Pazdur R
    Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Indication for Cancer Drug Based on Biomarkers.
    Aschenbrenner DS
    Am J Nurs; 2017 Sep; 117(9):22. PubMed ID: 28837483
    [No Abstract]   [Full Text] [Related]  

  • 6. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
    Fernández A
    Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
    Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.
    Garber K
    Nat Biotechnol; 2017 Apr; 35(4):297-298. PubMed ID: 28398313
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
    Yu Y
    Front Med; 2018 Apr; 12(2):229-235. PubMed ID: 29209918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
    Prasad V; Kaestner V; Mailankody S
    JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
    [No Abstract]   [Full Text] [Related]  

  • 13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Tissue-Agnostic Drug Approval Issued.
    Cancer Discov; 2017 Jul; 7(7):656. PubMed ID: 28583911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 16. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
    Ruiz-Bañobre J; Goel A
    Gastroenterology; 2019 Mar; 156(4):890-903. PubMed ID: 30578781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
    Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
    Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
    Considine B; Petrylak DP
    Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name.
    Wolchok JD; Callahan MK
    Cancer J; 2018; 24(1):1. PubMed ID: 29360720
    [No Abstract]   [Full Text] [Related]  

  • 20. Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care.
    Cheng ML; Solit DB
    Ann Intern Med; 2018 Feb; 168(3):221-222. PubMed ID: 29310131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.